Revvity HTRF cIAP1 BIR2 Binding Kit, 10,000 Assay Points

A fast and easy way to identify and characterize new binders to cIAP1 protein targeting BIR2 domain.

cIAP1, also named BIRC2, is a member of the Inhibitor of Apoptosis Proteins (IAP) family. IAP proteins are involved in multiple biological processes, such as innate immunity and play an important role in apoptosis inhibition.

cIAP1 overexpression has been associated with cancer resistance, making it an attractive target in cancer therapy, where several therapeutic strategies are investigated such as SMAC mimetics.

Moreover, cIAP1 displays E3 ligase activity and leads to targeted proteins ubiquitination and their subsequent degradation, such property being exploited through Proteolysis-targeting chimeras (PROTACs) strategy. Indeed, SNIPERs molecules (Specific and Non-genetic inhibitor of apoptosis protein [IAP]-dependent Protein Erasers) can induce the degradation of both the targeted proteins and IAPs and is expected to harness cancer cells killing.

Therefore, new compounds targeting cIAP1 which exhibit dual role i) inhibition of cIAP1 anti-apoptotic function and ii) induction of targeted protein degradation represent a promising therapeutic approach.

cIAP1, like other IAP family proteins, contains BIR domains which interact with IAP-binding motif of partners such as caspases. This interaction has been suggested to control pro- and anti-apoptotic activities.

cIAP1 compounds characterization on BIR2 and BIR3 domains enables accurate profiling and selectivity studies.